FUNDAMENTALS · Fundamentals · JP Healthcare

PHC Holdings (6523) Fundamentals 2026 — P/E 286.2x, Revenue Analysis | SniperIQ

PHC Holdings (6523) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥139.4B, trading at ¥1102.00 on the JPX. This SniperIQ fundamentals page covers PHC Holdings's valuation (P/E 286.2x, P/B 0.9x), profitability (net margin 0.1%), revenue (¥364.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥139.4B
P/E (TTM)286.2x
Net Margin0.1%
Revenue (FY25)¥364.4B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is PHC Holdings's market cap?

PHC Holdings (6523) has a market capitalization of approximately ¥139.4B, trading at ¥1102.00 on the JPX. Market cap moves with the live share price.

What is PHC Holdings's P/E ratio?

PHC Holdings's trailing twelve-month P/E ratio is 286.2x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is PHC Holdings?

PHC Holdings runs a net profit margin of 0.1%, a gross margin of 45.4%, and an operating margin of 5.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does PHC Holdings generate?

PHC Holdings reported revenue of ¥364.4B for fiscal year 2025, with net income of ¥492M and earnings per share (EPS) of 3.89. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does PHC Holdings pay a dividend?

PHC Holdings offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is PHC Holdings financially healthy?

PHC Holdings carries a debt-to-equity ratio of 1.45x and a current ratio of 0.93x, with a market beta of 0.64. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is PHC Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PHC Holdings (6523) the key facts are: market cap ¥139.4B, P/E 286.2x, revenue ¥364.4B, 52-week range 878-1189. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track PHC Holdings's full fundamentals live

Get PHC Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Alivus Life Sciences (ALIVUS) fundamentals · GNI Group (2160) fundamentals · Ilyang Pharmaceutical (007570) fundamentals · CVS Health (CVS) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons